title: Gingival involvement in a patient with CD56+ chronic myelomonocytic leukemia.
abstract: Leukemic infiltration of the gingiva is most commonly reported to be associated with monocytic subtypes of acute myeloblastic leukemia (AML) but rarely with myelodysplastic syndromes (MDS). Here we report a case of CD56+ chronic myelomonocytic leukemia (CMML) who developed gingival involvement simultaneously when the leukocyte count elevated. At that time no increase in peripheral or bone marrow blasts were observed. Gingival hypertrophy regressed with the treatment of hydroxyurea. Three months later, bone marrow blast count elevated and the patient was treated with two courses of AML-like regimen and then one course of consolidation therapy. The patient is in complete hematological remission for one and a half years. Similar to other extramedullary involvements, gingival hypertrophy in CMML can be a harbinger of the disease entering a more aggressive phase requiring systemic chemotherapy.
authors.affiliation: Dokuz Eylul University School of Medicine, Division of Hematology-Oncology, Izmir, Turkey.
authors.forename: Filiz
authors.initials: F
authors.lastname: Vural
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Ozcan
authors.forename: G Hayri
authors.initials: GH
authors.lastname: Ozsan
authors.forename: Fatih
authors.initials: F
authors.lastname: Demirkan
authors.forename: Ozden
authors.initials: O
authors.lastname: Piskin
authors.forename: Halil
authors.initials: H
authors.lastname: Ates
authors.forename: Aydanur
authors.initials: A
authors.lastname: Kargi
authors.forename: Bulent
authors.initials: B
authors.lastname: Undar
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000096:biosynthesis; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis; D001853:Bone Marrow / Q000473:pathology; D019002:CD56 Antigen / Q000096:biosynthesis*; D002467:Cell Nucleus / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D005881:Gingiva / Q000473:pathology; D005887:Gingival Neoplasms / Q000473:pathology* / Q000556:secondary; D006801:Humans; D006984:Hypertrophy; D016130:Immunophenotyping; D007621:Karyotyping; D015477:Leukemia, Myelomonocytic, Chronic / Q000378:metabolism*; D011379:Prognosis; D012307:Risk Factors; D012509:Sarcoma / Q000473:pathology; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D019002:CD56 Antigen; C067980:CD68 antigen, human; D000097382:CD68 Molecule